SCHEMBL6494299

SCHEMBL6494299

CC(C)(C)OC(=O)N1CC[C@H]2Nc3c(C(=O)O)cccc3[C@H]2C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.43
USP30 Q70CQ3 4/20 0.41
PARP1 P09874 3/20 0.41
JAK2 O60674 2/20 0.40
JAK1 P23458 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
HPGDS O60760 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RORC P51449 1/20 0.39
STS P08842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6494303 1.00 GPR119 (0.43) GPR119USP30PARP1JAK2JAK1
SCHEMBL1842912 0.84 USP30 (0.41) GPR119USP30JAK2JAK1MEN1
SCHEMBL1843411 0.84 GPR119 (0.42) GPR119USP30PARP1JAK2JAK1
SCHEMBL1840393 0.84 USP30 (0.41) GPR119USP30JAK2JAK1MEN1
SCHEMBL5133430 0.84 USP30 (0.41) GPR119USP30JAK2JAK1MEN1
SCHEMBL1842914 0.84 USP30 (0.41) GPR119USP30JAK2JAK1MEN1
SCHEMBL1840952 0.83 GPR119 (0.44) GPR119USP30PARP1JAK2JAK1
SCHEMBL1844577 0.83 GPR119 (0.44) GPR119USP30PARP1JAK2JAK1
SCHEMBL1844576 0.83 GPR119 (0.44) GPR119USP30PARP1JAK2JAK1
SCHEMBL5133257 0.81 GPR119 (0.47) GPR119USP30JAK2JAK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849619-B2 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-01 US disclosed
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-09-23 US disclosed
US-6699852-B2 ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-02 US disclosed
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 GPR119 27/4885USP30 4592/4885PARP1 2614/4885
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 GPR119 27/4885USP30 4592/4885PARP1 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.